Top Line Results Favor Victoza In Large Cardiovascular Outcomes Trial

Novo Nordisk today announced top-line positive results of the LEADERS trial, the cardiovascular outcomes trial testing its diabetes drug Victoza (liraglutide). Liraglutide is a GLP-1 inhibitor used to help achieve glucose control in patients with type 2 diabetes. 9,340 people with type 2 diabetes were randomized to liraglutide or placebo in LEADERS for 3.5 –...Click here to continue reading...

Source: CardioBrief - March 4, 2016 Category: Cardiology Authors: Larry Husten Tags: Diabetes People, Places & Events CVOT liraglutide Victoza Source Type: blogs